Safety
503A vs 503B: What the Difference Means for Your Medication
One is state-overseen, one is FDA-registered. Neither means the product is approved.
Providers cite "503B" as a quality signal and "FDA-registered" as reassurance, but the two compounding pathways are widely misunderstood. This piece explains 503A and 503B in plain terms and states clearly why neither makes any compounded GLP-1 product FDA-approved.
503A: the traditional compounding pathway
A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients pursuant to a prescription. It's overseen mainly by the state board of pharmacy and must follow USP standards, including USP standards for sterile compounding when it prepares injectables. It is not registered with FDA as a manufacturer, and its products are not FDA-approved. This is the lawful, ordinary route for patient-specific compounding — not an inferior one.
503B: the outsourcing-facility pathway
A 503B outsourcing facility, created by the Drug Quality and Security Act of 2013, may compound larger batches — within legal limits and sometimes without patient-specific prescriptions — under current good manufacturing practice (cGMP) requirements, and it registers with and is inspected by FDA. That's more manufacturing-style oversight than a 503A pharmacy carries. But registration is a facility status renewed annually, and it is still not product approval: 503B products are not FDA-approved.
The distinction that gets misread
The phrase "FDA-registered 503B facility" is routinely read as "FDA-approved product." It isn't. FDA registration of the facility means the facility is subject to FDA oversight; it says nothing about premarket review of the specific compounded formulation, which does not happen for compounded drugs. FDA's compounding guidance is explicit that compounded drugs — from either pathway — are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
| Dimension | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Primary oversight | State board of pharmacy | FDA (cGMP, inspections) |
| Prescription | Patient-specific required | May compound without patient-specific Rx |
| Batch size | Individual preparations | Larger batches (within limits) |
| Product FDA-approved? | No | No |
What this means when choosing a provider
Both pathways are legitimate; neither guarantees quality on its own. What matters is verifying the specific facility: confirm 503B claims against FDA's registered-outsourcing-facility list and 503A licenses against the state board, using the four-step verification workflow. A provider's pathway claim is a starting point, not proof.
Primary sources
This article's regulatory and safety statements draw on the following primary sources from the U.S. Food and Drug Administration:
- FDA — FD&C Act Provisions that Apply to Human Drug Compounding (503A vs 503B)
- FDA — Information for Outsourcing Facilities (503B registration)
- FDA — Registered Outsourcing Facilities (503B list)
Frequently asked questions
Is a 503B product safer than a 503A product?
503B facilities carry cGMP requirements and FDA inspection, which is more manufacturing-style oversight — a meaningful difference. But neither product is FDA-approved, and a well-run 503A pharmacy following USP sterile-compounding standards is the lawful route for patient-specific compounding. Verify the specific facility rather than assuming one pathway is uniformly safer.
Does "FDA-registered" mean the medication is approved?
No. Registration is a facility status that subjects the facility to FDA oversight; it is never approval of the product. No compounded semaglutide or tirzepatide is FDA-approved, in any formulation, from any facility type. Read "FDA-registered" as oversight, not approval.
How do I confirm a 503B claim?
Check FDA's published list of registered outsourcing facilities for the pharmacy's legal name. If it's not listed, the 503B claim isn't verified. For a 503A pharmacy, confirm the license on the state board's lookup. The verification workflow walks through both.
Evidence status. Pricing figures are provider-reported or independently calculated as of 2026-07-20, not checkout-verified. Compounded medications are not FDA approved. This article is consumer education, not medical advice. See the methodology for how figures are gated and the public evidence ledger for per-figure sources. Found an error? Use the corrections route.